Xenon Pharmaceuticals Inc.
NASDAQ:XENE · NASDAQ Global Market
-$0.29 today
Vol 1.90M · Avg 1.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-59.5%
avg -35.0%
ROIC
-39.6%
avg -31.8%
ROA
-35.2%
avg -28.3%
Analysis
ROA is currently the strongest return metric at -35.2% versus its period average of -28.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ian C. Mortimer | President, Chief Executive Officer & Director | $1.38M | — | 50 | $19,923.00 | 0.03% |
Christopher John Kenney | Chief Medical Officer | $848,652.00 | — | 55 | $7,069.00 | <0.01% |
Andrea DiFabio | Chief Legal Officer & Corporate Secretary | $766,152.00 | — | 58 | $7,301.00 | <0.01% |
Darren S. Cline | Chief Commercial Officer | $619,768.00 | — | 62 | $40,000.00 | 0.05% |
Robin Sherrington | Executive Vice President of Strategy & Innovation | $587,028.00 | — | 65 | $65,000.00 | 0.08% |
Thomas Patrick Kelly | Chief Financial Officer | $515,697.00 | — | 55 | $10,507.00 | 0.01% |
James R. Empfield | Executive Vice President of Drug Discovery | $323,428.00 | — | 65 | $65,000.00 | 0.08% |
Shelley McCloskey | Executive Vice President of Human Resources | — | — | 66 | — | — |
Colleen Alabiso | Senior Vice President of Corporate Affairs | — | — | — | — | — |
Matthew D. Ronsheim | Chief Operating Officer | — | — | 54 | $1,593.00 | <0.01% |
Gilbert | Senior Director | — | — | — | — | — |
Shelley McClCoskey | Executive Vice President of Human Resources | — | — | 66 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
24
$21.91M
Net Sentiment
$21.91M
Net selling
Most Active
MORTIMER IAN
18 transactions
1–10 of 24
Analysis
Insiders reported 0 buys worth $0.00 and 24 sells worth $21.91M over the last 12 months. That adds up to net selling of $21.91M. MORTIMER IAN was the most active insider with 18 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +2.9% | +33.6% (15yr)13 analysts |
| Net Income | N/A | N/A | N/A | N/A13 analysts |
| EBIT | N/A | N/A | N/A | N/A13 analysts |
Analysis
Recent growth has been strongest in Revenue at +2.9% over three years. Forward estimates point to Revenue at +33.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.16B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.64B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.44B
Legend Biotech Corporation
NASDAQ:LEGN
$5.44B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.38B
Travere Therapeutics, Inc.
NASDAQ:TVTX
$5.06B
Celcuity Inc.
NASDAQ:CELC
$4.07B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.69B
Zai Lab Limited
NASDAQ:ZLAB
$2.09B
Ascentage Pharma Group International
NASDAQ:AAPG
$403.00M
Who manages XENE?
Xenon Pharmaceuticals Inc. (XENE) lists 12 active executives. The top listed executive is Darren S. Cline, Chief Commercial Officer.
Are XENE insiders buying or selling?
Recent insider activity shows net buying of $76.58M.
Explore More
Continue the stock analysis
Jump to another research area for this company.